<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="24229">Geranylgeraniol</z:chebi>, a polyprenylalcohol composing the side chain of vitamin K2 (VK2), was previously reported to be a potent inducer of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines (Ohzumi H et al, J Biochem 1995; 117: 11-13) </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ability of VK2 (menaquinone 3 (MK3), MK4 and MK5) and its derivatives such as phytonadione (VK1), as well as polyprenylalcohols with side chains of various lengths including <z:chebi fb="1" ids="28600">farnesol</z:chebi> (C15-OH; FO), <z:chebi fb="0" ids="24229">geranylgeraniol</z:chebi> (C20-OH; GGO), and geranylfarnesol (C25-OH; GFO) toward <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>MK3, MK4, MK5 and GFO (at 10 microM) showed a potent <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing activity for <z:hpo ids='HP_0000001'>all</z:hpo> freshly isolated <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells tested and for <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines such as NB4, an <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> (APL)-derived cell line and MDS92, a cell line derived from a patient with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, although there were some differences depending on the cells tested </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, VK1 showed no effect on any of the <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="4" pm="."><plain>The combination of MK5 plus <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) resulted in enhanced induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in both freshly isolated APL cells and NB4 cells as compared to each reagent alone </plain></SENT>
<SENT sid="5" pm="."><plain>These data suggest the possibility of using VK2 and its derivatives for the treatment of myelogenous <z:hpo ids='HP_0001909'>leukemias</z:hpo>, including APL </plain></SENT>
</text></document>